Crohn's disease

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Athos Therapeutics Announces their Corporate Circle Membership to the Crohn's & Colitis Foundation and Participation in the "IBD Innovate" Conference

Wednesday, October 13, 2021 - 4:00pm

At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.

Key Points: 
  • At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.
  • The Company is developing precision therapeutics by the stratification of IBD patients into specific molecular subtypes.
  • "Our membership with the Crohn's & Colitis Foundation will enhance our collaborative efforts with the foundation, FDA, and other pharmaceutical companies to develop IBD precision therapeutics.
  • The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD).

Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

Tuesday, October 12, 2021 - 12:00pm

NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.

Key Points: 
  • NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.
  • The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.
  • The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.

PE GI Solutions Announces the Official Integration of Gastroenterology and Liver Specialists of Tidewater with Capital Digestive Care

Tuesday, October 5, 2021 - 3:55pm

JAMISON, Pa., Oct. 5, 2021 /PRNewswire/ -- PE GI Solutions (formerly Physicians Endoscopy) announced the integration of Gastroenterology and Liver Specialists of Tidewater (GLST) with their strategic partner, Capital Digestive Care.

Key Points: 
  • JAMISON, Pa., Oct. 5, 2021 /PRNewswire/ -- PE GI Solutions (formerly Physicians Endoscopy) announced the integration of Gastroenterology and Liver Specialists of Tidewater (GLST) with their strategic partner, Capital Digestive Care.
  • PE GI Solutions partners with GI physicians through its practice and center solutions platforms to streamline operations and diversify and enhance revenue streams.
  • "PE GI Solutions looks forward to supporting the growth and expansion of Gastroenterology and Liver Specialists of Tidewater and Capital Digestive Care through this integration," said David Young, President and CEO of PE GI Solutions.
  • This integration marks an exciting milestone for Gastroenterology and Liver Specialists of Tidewater, Capital Digestive Care, and PE GI Solutions, demonstrating the continued growth and expansion of the MSO and the continued commitment to deliver quality patient care to the Mid-Atlantic.

Inventors Mary and Jason Young and Hydropolis, Inc. Have Signed a Patent License Agreement for Multi-Cooker Designed for Use With Cannabis

Monday, October 4, 2021 - 1:48pm

NEW PORT RICHEY, Fla., Oct. 4, 2021 /PRNewswire/ --Inventors Mary and Jason Young and Hydropolis, Inc. sign patent license agreement.

Key Points: 
  • NEW PORT RICHEY, Fla., Oct. 4, 2021 /PRNewswire/ --Inventors Mary and Jason Young and Hydropolis, Inc. sign patent license agreement.
  • Mary and Jason Young today announced that they have signed a patent license agreement with Hydropolis, Inc. which covers the use of US Patent No.
  • The agreement grants Hydropolis, Inc., located in West Springfield, Massachusetts, an exclusive license to sell their kitchen appliance, Butter Brewer, using the patented technology.
  • I connected online with the cannabis community and learned how to make cannabis oil eventually leading to our invention," said Mary Young.

Enterome to Attend Upcoming Conferences

Monday, October 4, 2021 - 11:00am

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health.

Key Points: 
  • Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health.
  • Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and inflammatory diseases:
    - OncoMimics: innovative, off-the-shelf, microbiome peptide powered cancer vaccines (EO2401, EO2463).
  • Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
  • Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

Enterome to Attend Upcoming Conferences

Monday, October 4, 2021 - 11:00am

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health.

Key Points: 
  • Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health.
  • Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and inflammatory diseases:
    - OncoMimics: innovative, off-the-shelf, microbiome peptide powered cancer vaccines (EO2401, EO2463).
  • Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
  • Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

Monday, October 4, 2021 - 6:01am

The study is designed to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remission in patients with Crohns Disease (CD).

Key Points: 
  • The study is designed to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remission in patients with Crohns Disease (CD).
  • The DIVERSITY clinical program design wasinformed by results from thePhase 2 FITZROY study, with filgotinib, whichprovidedpositive results for the use of this JAK1 inhibitorin patients with active CD.
  • In agreement with Gilead, Galapagos will assume sponsorship of and operational and financial responsibility for the ongoing DIVERSITY clinical study, evaluating filgotinib in CD, and its long-term extension study.
  • From April 1, 2022, Galapagos will also be solely responsible for all development costs for the DIVERSITY clinical study.

At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study

Friday, October 1, 2021 - 2:00pm

Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.

Key Points: 
  • Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.
  • Among patients treated with mirikizumab, results in symptomatic remission, rectal bleeding remission and stool frequency remission were comparable between biologic-nave patients and those who had prior experience with biologics.
  • Efficacy and Safety of Mirikizumab in Patients with Ulcerative Colitis: 104-Week Results from a Phase 2 Randomized Controlled Trial
    186 patients with moderately to severely active UC received treatment with mirikizumab.
  • At two years, 85.9% (67/78) of patients achieved rectal bleeding remission and 84.6% (66/78) of patients achieved stool frequency remission.